MedTrace Logo

Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis

NCT03585946 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2026-01-16

No results posted yet for this study

Summary

This is a prospective, multicenter cohort observational; study to compare treatment outcomes in patients admitted to the hospital with Stevens-Johnsons Syndrome/Toxic Epidermolysis, aiming to assess the utility of medical management. The hypothesis of this study is that one or more treatment options will demonstrate improved patient outcomes. The primary objectives are cessation of progression of disease, time to complete re-epithelialization, length of stay, and mortality rate in the treatment groups as compared to those receiving supportive care alone. Exploratory analyses will assess the cause, risk factors, and severity prediction factors associated with the disease.

Conditions

  • Stevens-Johnson Syndrome
  • Toxic Epidermal Necrolysis
  • Drug Reaction

Interventions

DRUG

Site specific standard of care comparison

Patients outcomes will be assessed and compared based on the medication they receive which will be assigned based on the standard of care at each enrolling site.

Sponsors & Collaborators

  • Massachusetts General Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2030-01-01
Primary Completion
2040-12-31
Completion
2040-12-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03585946 on ClinicalTrials.gov